Business Context and Reporting Period
Company: Surgery Partners, Inc. (SGRY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Surgery Partners operates a national network of 161 surgical facilities (142 Ambulatory Surgery Centers and 19 surgical hospitals) across 31 states. The company partners with physicians and healthcare systems to provide outpatient surgical services, primarily in orthopedics, pain management, ophthalmology, and gastroenterology. As of December 31, 2024, the company consolidated 118 facilities for financial reporting purposes.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $3,114.3 | $2,743.3 | +13.5% |
| Operating Income | $348.8 | $328.0 | +6.3% |
| Net Income (GAAP) | $12.5 | $135.3 | -90.8% |
| Net Loss Attributable to Surgery Partners | $(168.1) | $(11.9) | Worsened |
| Adjusted EBITDA | $508.2 | $438.1 | +16.0% |
| Cash Flow from Operations | $300.1 | $293.8 | +2.1% |
| Cash and Cash Equivalents | $269.5 | $195.9 | +37.6% |
| Total Debt (Principal) | ~$3.4 billion | ~$2.8 billion | Increased |
Debt Structure: As of December 31, 2024, total indebtedness included approximately $1.4 billion in senior secured term loans, $800.0 million in senior unsecured notes due 2032, and $192.0 million in borrowings under a revolving credit facility. The company also holds approximately $1.0 billion in notes payable and finance lease obligations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13.5% to $3.1 billion, driven by an 8.0% increase in days-adjusted same-facility revenue (comprising a 3.9% increase in case volume and 4.0% increase in revenue per case) and acquisitions completed in 2024.
- Profitability Divergence: While Adjusted EBITDA grew 16.0% to $508.2 million, GAAP Net Loss attributable to the company widened significantly to $168.1 million from a loss of $11.9 million in 2023. This was primarily due to a $134.6 million increase in income tax expense (driven by a valuation allowance increase) and higher non-controlling interest allocations.
- Acquisition Activity: The company acquired a controlling interest in eight surgical facilities and several physician practices for aggregate cash consideration of $378.8 million (net of cash acquired).
- Debt Refinancing: In April 2024, the company issued $800.0 million in 7.250% senior unsecured notes due 2032 to redeem existing notes. In June 2024, the company amended its credit agreement to refinance term loans, reducing the interest rate margin.
- Transaction Costs: Transaction and integration costs rose to $100.1 million in 2024 from $61.7 million in 2023.
Guidance, Outlook, and Risks
Management Commentary: Management continues to focus on same-facility performance, selective acquisitions, and portfolio management. The company believes cash flows from operations, available cash, and revolver capacity are adequate to meet short- and long-term liquidity needs.
Subsequent Event (Critical): On January 27, 2025, Bain Capital Private Equity, LP (which owns approximately 39.3% of the company) submitted an unsolicited, non-binding proposal to acquire all outstanding shares not already owned by Bain Capital for $25.75 per share in cash.
Key Risks and Contingencies:
- Regulatory Compliance: Significant exposure to federal and state healthcare laws, including the Anti-Kickback Statute and Stark Law. The company notes its facilities do not fully satisfy safe harbor requirements, creating potential liability for penalties or exclusion from government programs.
- Payor Mix: Dependence on third-party payors (53.5% private insurance, 41.1% government). Reductions in reimbursement rates or changes in payor mix could materially impact revenue.
- Cybersecurity: The company experienced an immaterial cybersecurity incident in May 2023 that disrupted Idaho facilities. Ongoing risks of data breaches and operational disruption remain.
- Interest Rate Risk: Variable rate debt exposes the company to interest rate fluctuations, though hedging instruments (swaps and caps) are in place.
Investor Verification Checklist
- Valuation Allowance Impact: Verify the sustainability of the $284.7 million valuation allowance against deferred tax assets, which drove the GAAP net loss despite positive Adjusted EBITDA.
- Debt Service Capacity: Assess the ability to service ~$3.4 billion in debt obligations given the high interest expense ($201.7 million) and reliance on operating cash flow.
- Acquisition Integration: Monitor the integration of the $378.8 million in 2024 acquisitions and the associated $100.1 million in transaction costs to ensure projected synergies are realized.
- Bain Capital Proposal: Evaluate the implications of the unsolicited $25.75 per share acquisition proposal from Bain Capital on future corporate strategy and stockholder value.
- Regulatory Exposure: Review ongoing government audits and the company's compliance posture regarding the Anti-Kickback Statute and Stark Law, given the explicit disclosure of non-compliance with safe harbors.